（央视财经《第一时间》）第二批获得中国人民银行科技创新债券风险分担工具支持的四家民营股权投资机 构发行的债券，将于明天到28日在银行间市场发行，预计将为科技创新企业注入更多长期发展资金。四家民 营股权投资机构拟发行科创债合计9.3亿元。 中国银行间市场交易商协会表示，下一步还将提高注册发行效率，用好风险分担工具，大力发展债券市场"科 技板"，引导更多金融资源投早、投小、投长期、投硬科技，助力我国实现高水平科技自立自强。 转载请注明央视财经 编辑：王一帆 基石资本执行总裁兼合伙人 王启文：这期投资方向都是科技方向，特别是半导体、人工智能、机器人、合成 生物、脑科学这些方向。给我们管的创投基金、股权投资基金带来了稳定、长期、低成本的资金。 股权投资机构是投早、投小、投硬科技的重要力量，此前他们很少进行债券融资。为支持这些机构发债，中 国人民银行专门创设了科创债风险分担工具，提供低成本再贷款资金，与地方政府等一起为股权融资机构发 债提供担保等支持。今年6月，首批获得央行分担工具增信的科创债发行。目前，13.5亿元的募集资金已有将 近50%投入实际使用，并撬动上百亿元资金支持科技创新。 盛景嘉成总裁 联合创始人 刘昊 ...

Core Viewpoint - Water Goat Co., Ltd. has shown a significant increase in stock price this year, but recent trading indicates a decline in the short term, raising questions about future performance and investor sentiment [1][2]. Financial Performance - For the period from January to September 2025, Water Goat achieved a revenue of 3.409 billion yuan, representing a year-on-year growth of 11.96%. The net profit attributable to shareholders was 136 million yuan, reflecting a substantial increase of 44.01% compared to the previous year [2]. - The company has distributed a total of 142 million yuan in dividends since its A-share listing, with 77.8142 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 25, Water Goat's stock price rose by 2.09% to 19.50 yuan per share, with a trading volume of 174 million yuan and a turnover rate of 2.50%, resulting in a total market capitalization of 7.605 billion yuan [1]. - The stock has increased by 47.50% year-to-date, but has seen a decline of 9.89% over the last five trading days, 11.84% over the last 20 days, and 9.60% over the last 60 days [1]. Shareholder Structure - As of November 10, the number of shareholders for Water Goat increased to 30,000, a rise of 10.64%. The average number of circulating shares per shareholder decreased by 9.61% to 11,966 shares [2]. - Notable changes in institutional holdings include Hong Kong Central Clearing Limited becoming the sixth largest shareholder with 8.1833 million shares, an increase of 5.6594 million shares from the previous period. New shareholders include Huaxia Domestic Demand Driven Mixed A and Caitong Asset Management [3]. Business Overview - Water Goat Co., Ltd. is based in Changsha, Hunan Province, and was established on November 1, 2012. It was listed on February 8, 2018. The company's main business involves the research, production, and sales of cosmetics, with the primary revenue sources being lotions and creams (81.84%), masks (17.32%), and other products (0.84%) [1][2].

11月25日，阿拉丁盘中上涨2.05%，截至13:48，报12.95元/股，成交3396.51万元，换手率0.79%，总市 值43.07亿元。 资金流向方面，主力资金净流入196.49万元，大单买入848.84万元，占比24.99%，卖出652.35万元，占 比19.21%。 截至9月30日，阿拉丁股东户数1.16万，较上期减少7.17%；人均流通股28729股，较上期增加7.72%。 2025年1月-9月，阿拉丁实现营业收入4.44亿元，同比增长17.59%；归母净利润5776.03万元，同比减少 20.41%。 分红方面，阿拉丁A股上市后累计派现2.41亿元。近三年，累计派现1.50亿元。 机构持仓方面，截止2025年9月30日，阿拉丁十大流通股东中，中欧医疗健康混合A（003095）、中欧 责任投资混合A（009872）、中欧行业成长混合(LOF)A（166006）退出十大流通股东之列。 责任编辑：小浪快报 阿拉丁今年以来股价涨14.27%，近5个交易日跌3.14%，近20日涨5.46%，近60日跌17.83%。 资料显示，上海阿拉丁生化科技股份有限公司位于上海市浦东新区新金桥路36号南塔16楼，成立日 ...

格隆汇11月25日丨亿帆医药(002019.SZ)在投资者互动平台表示，合成生物项目处于竣工验收调试阶 段。 （原标题：亿帆医药(002019.SZ)：合成生物项目处于竣工验收调试阶段） ...

Core Insights - The article highlights the development of the Zhoushan Grain Industry Park, which focuses on deep processing of corn and aims to become a hub for synthetic biology and grain oil industry in the Yangtze River Delta region [1][2][3] Group 1: Company Developments - Zhoushan Huakang Biotechnology Co., Ltd. processes corn into various high-value products, significantly increasing their worth by dozens to hundreds of times [1] - The company has invested in a corn deep processing project with a total investment of 2.5 billion yuan, aiming for an annual production capacity of 2 million tons [1] - The first phase of the project is expected to generate an annual output value exceeding 3 billion yuan, while the synthetic biology production line is projected to reach 5 billion yuan [2] Group 2: Industry Growth and Strategy - The Zhoushan Grain Industry Park accounts for nearly 20% of the national import grain logistics volume and has a grain processing capacity of 4 million tons annually, with a processing output value close to 10 billion yuan [1] - The local government is focusing on building a circular economy in the grain oil industry and enhancing the synthetic biology sector, aiming to establish a "large project - industrial chain - industrial cluster" development model [2] - Over 1,000 acres of land have been planned for synthetic biology industry investment, equipped with necessary facilities for wastewater and solid waste treatment [3]

在医药行业转型升级的关键期，华润双鹤正以清晰的战略布局书写高质量发展答卷。华润双鹤董事长陆文超日前在接受中国证券报记者专访时表示，华润 双鹤的发展始终与国家战略、民众需求同频共振，通过深耕集采锤炼全价值链硬实力，以"处方药龙头打造+合成生物突破"双轮驱动构建核心竞争力，更 依托国际化布局拓宽发展边界，为企业长远发展注入强劲动能。 华润双鹤总部大楼 华润双鹤供图 构建全价值链硬实力 "华润双鹤的发展轨迹，始终与国家战略部署、民众健康需求紧密相连。"陆文超表示，从地方药企到全国性集团，从规模扩张到高质量发展，公司每一次 转型都紧扣时代脉搏，在顺应变革中实现可持续发展。"如今华润双鹤已构建起覆盖抗感染、慢病、专科等多个领域的产品体系，既在市场变化中保持稳 健活力，也为守护国民健康持续发力。" 国家药品集中带量采购政策的落地，成为华润双鹤锤炼核心能力的重要契机。陆文超表示，政策推出以来，公司便确立了积极拥抱的战略方向，旨在通过 深度参与集采获取政策红利。截至目前，公司累计有近60个产品在国家集采中中标，超过70%的产品在省级及联盟集采中中选。 "参与集采，是我们构建全价值链低成本能力的'牛鼻子'和核心纽带。"陆文超说 ...

Core Viewpoint - Jincheng Pharmaceutical's stock has shown a significant increase of 41.23% year-to-date, despite recent declines in the last five, twenty, and sixty trading days [1][2]. Company Overview - Jincheng Pharmaceutical, established on January 12, 2004, and listed on June 22, 2011, is located in Zibo City, Shandong Province. The company specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [2]. - The revenue composition of Jincheng Pharmaceutical includes: 34.59% from formulation products, 26.61% from other pharmaceutical chemical products, 21.88% from cephalosporin side chain active esters, and 16.92% from biopharmaceuticals and specialty APIs [2]. Financial Performance - For the period from January to September 2025, Jincheng Pharmaceutical reported revenue of 1.932 billion yuan, a year-on-year decrease of 23.19%, and a net profit attributable to shareholders of 31.577 million yuan, down 79.10% year-on-year [2]. - The company has distributed a total of 933 million yuan in dividends since its A-share listing, with 323 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Jincheng Pharmaceutical had 26,700 shareholders, an increase of 0.46% from the previous period, with an average of 13,903 circulating shares per shareholder, a decrease of 0.46% [2][3]. - Notable shareholders include the fourth-largest shareholder, Fortune Precision Medical Flexible Allocation Mixed A, holding 4.961 million shares, and the eighth-largest shareholder, Hong Kong Central Clearing Limited, holding 3.336 million shares, which decreased by 2.135 million shares from the previous period [3].

Core Insights - The core viewpoint of the articles emphasizes Huaxi Biological's strategic adjustments and focus on synthetic biology as a key growth area, aiming for high-quality development through technological innovation and organizational restructuring [1][4][12] Company Strategy - Huaxi Biological is actively adjusting its business and organizational structure to enhance its long-term competitiveness, focusing on core advantages and technological innovation [1][4] - The company is prioritizing C-end business development, aiming to create value for consumers by accurately defining brand positioning and target demographics [4][5] - The strategic focus on synthetic biology, particularly glycomics, is seen as a critical area for future growth and innovation [1][6] Financial Performance - In Q3 2025, Huaxi Biological reported a net profit of 0.32 billion yuan, a year-on-year increase of 55.63%, and revenue of 9.03 billion yuan, indicating sustained improvement following strategic reforms [4] - The company has successfully reduced its sales expense ratio to 34.26%, the lowest level in five years, while still achieving significant profit growth despite asset impairment provisions [5] Research and Development - Huaxi Biological is building an integrated platform for research and development, focusing on glycomics and cell biology to provide systematic solutions for aging intervention [6][9] - The company has developed a synthetic biology system supported by two core platforms: a biocatalyst library and a pilot-scale conversion platform, which facilitate rapid molecule screening and scaling [6][10] Technological Advancements - The company has achieved global leadership in technologies such as the precise synthesis of heparin through enzyme methods, moving towards "green biological manufacturing" [7] - Huaxi Biological's pilot-scale platform is crucial for validating technologies and facilitating the transition from laboratory breakthroughs to industrial applications [10][11] Future Outlook - The company aims to deepen its "pilot-scale foundation, AI efficiency enhancement" model, aligning with national strategies to solidify its position in the synthetic biology industry [12]

Core Insights - The company is actively adjusting its operations and organizational structure to enhance its long-term competitiveness through technological innovation, focusing on synthetic biology as a core strategic direction [1][2][4] Group 1: Strategic Adjustments and Financial Performance - The company has seen a profit growth trend, achieving a net profit of 0.32 billion yuan in Q3 2025, a year-on-year increase of 55.63%, with operating revenue reaching 9.03 billion yuan [1] - The decline in revenue during the first three quarters was primarily due to a decrease in skin science innovation conversion business, which is viewed as a temporary outcome of the ongoing adjustments [2] - The company has reduced sales expenses to 34.26%, the lowest level in five years, while still achieving approximately 55% profit growth year-on-year [3] Group 2: Focus on C-end Business - The C-end business is a key focus of the company's adjustments, emphasizing the need to accurately define brand positioning and target demographics to create consumer value [2] - The company is building an ecosystem that fosters collaboration with users, platforms, and partners to strengthen its C-end business foundation [2][3] Group 3: Synthetic Biology and Research Platforms - The company is centered on synthetic biology, particularly in glycoscience and cell biology, aiming to provide systematic solutions for delaying aging [4][5] - The synthetic biology system is supported by two core platforms: a biocatalyst library and a pilot transformation platform, which facilitate rapid molecular screening and scale-up verification [5][7] - The company has developed leading technologies, such as the precise synthesis of heparin through an enzyme-based method, moving towards "green biological manufacturing" [5] Group 4: Pilot Testing and AI Integration - The pilot platform is crucial for connecting research, validation, and transformation, and is seen as a strategic asset in the innovation chain [7][8] - The company has invested in a pilot transformation platform in Tianjin, equipped with fermentation systems and production lines to support scaling and standardization [7] - The pilot platform is open to collaboration with universities and research institutions, providing low-cost support for technology validation and process development [8][9]

Core Viewpoint - China Resources Double Crane is strategically positioning itself for high-quality development in the pharmaceutical industry by aligning with national strategies and public health needs, focusing on a dual approach of prescription drug leadership and breakthroughs in synthetic biology [1][3]. Group 1: Strategic Development - The company has established a comprehensive product system covering multiple fields such as anti-infection, chronic diseases, and specialized areas, maintaining robust vitality amid market changes [1]. - The implementation of the national drug centralized procurement policy has provided an opportunity for the company to enhance its core capabilities, with nearly 60 products winning bids in national procurement and over 70% in provincial and alliance procurements [1][2]. Group 2: Cost Control and Marketing Strategy - Participation in centralized procurement is seen as a key to building low-cost capabilities across the entire value chain, necessitating industry-leading cost control and large-scale production advantages [2]. - The company has optimized its marketing strategy by developing differentiated promotion tactics for different product types, focusing on broad coverage for key products and specialized promotion for non-procurement products [2]. Group 3: R&D and Innovation - The company has increased its R&D investment intensity from 3.7% to nearly 8%, while maintaining sustainable revenue and profit growth through a strategy of cost control, precise R&D, and model innovation [3][5]. - The company has adopted a "precise project initiation + risk control" approach to enhance R&D efficiency and has established overseas authorization evaluation standards to validate R&D quality [2][5]. Group 4: Growth Strategy - The company aims to establish itself as the "number one brand in prescription drugs" and to create a second growth curve through synthetic biology technology, with external mergers and acquisitions being a key strategy [3][4]. - Recent acquisitions, such as that of Henan Zhongshuai, exemplify the company's strategy to enhance its product pipeline and profitability while addressing unmet clinical needs [3][4]. Group 5: Internationalization - The company has developed an international network covering over 50 countries, focusing on raw material drug exports, and aims to extend its reach into formulation exports during the "14th Five-Year Plan" [6][7]. - The internationalization strategy includes establishing production bases for complex injectables and leveraging tax incentives in Hainan to create an international production base in the health sector [6][7].